RAC.AX Race Oncology up 27.78% intraday 19 Mar 2026: catalyst-driven move to monitor

RAC.AX stock jumped 27.78% to A$2.76 intraday on 19 Mar 2026, making Race Oncology Limited a top gainer on the ASX. Volume surged to 307,283 shares versus an average of 164,099, signalling fresh buying interest. The move came without a large corporate transaction announced on the company site, so traders appear to be pricing clinical and sector catalysts into the stock. We track how these intraday flows connect to clinical timelines, valuation metrics, and Meyka AI’s short and medium-term forecasts.

RAC.AX stock: intraday move and immediate drivers

Race Oncology Limited (RAC.AX, ASX) rose 27.78% intraday to A$2.76 on 19 Mar 2026. Trading volume was 307,283, or 1.87x the average, which often amplifies biotech moves tied to trial updates or speculative flows. The stock opened at A$2.42 and hit an intraday high of A$2.85, showing aggressive buying near resistance around the 50-day moving average of A$2.44.

RAC.AX stock fundamentals and valuation

Race Oncology reports EPS of -0.05 and a trailing PE of -47.60, reflecting negative earnings typical for clinical-stage biotech. Market capitalisation is A$432.50M with 181,723,930 shares outstanding. Price-to-book is 17.76 and price-to-sales is 548.57, indicating the stock trades at premium multiples compared with mature healthcare companies. These ratios reflect R&D upside expectations but also higher downside risk if trial outcomes disappoint.

RAC.AX stock technical snapshot and liquidity

Technically, RAC.AX sits above the 50-day (A$2.44) and 200-day (A$2.34) averages, a short-term bullish sign. RSI is 52.35, MACD near neutral, and Bollinger Bands read upper A$2.51, middle A$2.32, lower A$2.13, implying room for both continuation and reversal. On liquidity, cash per share is A$0.12, implying roughly A$21.61M in cash on the balance sheet, supporting operations through near-term clinical spend.

RAC.AX stock: clinical catalysts and sector context

Race Oncology is advancing Zantrene in Phase II/III trials for melanoma and clear cell renal cell carcinoma. Clinical milestones and investigator updates remain the primary fundamental drivers of RAC.AX stock performance. The broader Healthcare sector on the ASX is down year-to-date 10.25%, which makes isolated biotech rallies more sensitive to idiosyncratic trial news and speculative flows.

Meyka AI rates RAC.AX with a score out of 100 and model forecasts

Meyka AI rates RAC.AX with a score out of 100: 68.99 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. This grade is informational only; it is not financial advice. Meyka AI’s forecast model projects a one-year price of A$3.39, implying +22.56% from the current A$2.76. The quarterly target is A$3.18 (+15.22%) and the monthly model sits at A$2.31 (-16.30%). Forecasts are model-based projections and not guarantees.

RAC.AX stock risks and opportunities for traders

Key risks include negative earnings, high valuation multiples, and binary clinical outcomes that can swing the stock substantially. Race Oncology has strong liquidity ratios such as a current ratio of 18.37, but cash burn depends on trial timelines. Opportunity sits with Zantrene’s trial readouts and potential licensing deals, which could materially re-rate the stock if outcomes are positive.

Final Thoughts

RAC.AX stock stands out as a top intraday gainer on 19 Mar 2026 after a 27.78% jump to A$2.76, driven by heavy volume and speculative clinical interest. Fundamentals show R&D-stage characteristics: EPS -0.05, PE -47.60, and premium valuation ratios such as PB 17.76. Technically, the price sits above the 50-day and 200-day averages, and momentum indicators are neutral. Meyka AI’s forecast model projects A$3.39 in one year, implying +22.56% upside versus the current price. Traders should balance that upside against binary trial risk, tight liquidity windows for biotech events, and sector headwinds. For real-time disclosures and trial updates, check Race Oncology’s site and ASX announcements. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are projections, not guarantees, and this is not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.